Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, P.R. China.
Department of Laboratory Medicine, Nantong Tumor Hospital, Nantong, P.R. China.
Curr Stem Cell Res Ther. 2019;14(6):482-494. doi: 10.2174/1574888X14666190228103230.
Recent studies have shown the great value of cell therapy over the past few decades. Mesenchymal stem cells (MSCs) have been reported to treat various degenerative diseases not through their differentiation potential but through their paracrine factors of the extracellular vesicle (EV) including exosomes. Exosomes are nanosized (70~150 nm) membrane-bound extracellular vesicles, not only involved in cell-to-cell communication but also in the development of tissue injury repair.
As more researchers proved the enormous potential of exosomes in the field of repairing damaged tissue currently, it is urgent to explore the concrete mechanism and make exosomes to be a practical treatment tool in clinical medicine. In our study, we analyzed and summarized the work on tissue repair via exosomes in order to give some suggestions about the application of exosomes in clinical reality in the future.
MSC-derived exosomes (MSC-Ex) contain a wide variety of functional proteins, mRNAs, miRNAs and signaling lipids. Compared with their parent cells, MSC-Ex are more stable and can reduce the inherent safety risks in administering viable cells such as the risk of occlusion in microvasculature. MSC-Ex can be used to develop a cell-free exosome-based therapy for regenerative medicine, and may provide an alternative to MSC-based therapy.
This review summarizes the most recent knowledge of therapeutic potential of MSC-Ex in the liver, heart, kidney, bone, brain diseases and cancer, as well as their associated challenges and opportunities.
近几十年来的研究表明,细胞疗法具有重要价值。间充质干细胞(MSCs)已被报道可通过其细胞外囊泡(EV)的旁分泌因子(包括外泌体)而非分化潜能来治疗各种退行性疾病。外泌体是纳米大小(70~150nm)的膜结合细胞外囊泡,不仅参与细胞间通讯,而且参与组织损伤修复的发展。
由于目前越来越多的研究人员证明了外泌体在修复受损组织领域的巨大潜力,因此迫切需要探索其具体机制,并使外泌体成为临床医学中的一种实用治疗工具。在本研究中,我们分析和总结了通过外泌体进行组织修复的工作,以便为未来外泌体在临床实践中的应用提供一些建议。
MSC 来源的外泌体(MSC-Ex)包含多种功能蛋白、mRNA、miRNA 和信号脂质。与亲本细胞相比,MSC-Ex 更稳定,可以降低活细胞给药固有的安全风险,例如微血管阻塞的风险。MSC-Ex 可用于开发基于无细胞外泌体的再生医学治疗方法,并且可能替代基于 MSC 的治疗方法。
本综述总结了 MSC-Ex 在肝脏、心脏、肾脏、骨骼、大脑疾病和癌症中的治疗潜力及其相关挑战和机遇的最新知识。